Aficamten Shows Added Benefits in HCM, But Core Risks Persist

What happened

On September 2, 2026, Zacks reported that Cytokinetics' aficamten demonstrated added benefits in HCM studies, suggesting improved prospects in both non-obstructive and obstructive disease. This news arrives after Myqorzo's U.S. approval and launch initiation in January 2026, and it may reflect positive data from the ACACIA-HCM trial in non-obstructive HCM, which was expected in Q2 2026. While the headline is positive, the report lacks specifics on magnitude and endpoints, and the master analysis has consistently cautioned that clinical differentiation alone may not overcome entrenched competition from Bristol Myers' Camzyos, which has a large treated base and simplified label. The company remains burdened by a leveraged balance sheet with negative equity and significant royalty obligations, and launch execution is still unproven with only early commercial traction. Therefore, this news is a modest positive that could boost sentiment but does not yet resolve the core uncertainties around Myqorzo's commercial ramp and the sustainability of the franchise beyond oHCM.

Implication

The added benefits could improve the probability of ACACIA success and expand the addressable market, but valuation already prices in high penetration. The key inflection remains real-world Myqorzo prescription trends and payer coverage, which are still early and unproven. If the news reflects positive ACACIA data, it may de-risk the nHCM opportunity but does not address the oHCM share battle against Camzyos. Given the crowded bullish positioning and insider selling, any disappointment in launch metrics or future trials could lead to sharp downside. Maintain a reduce/avoid stance until sustained commercial traction or clearer pricing/volume data confirm the bull case; consider trimming on strength toward $80.

Thesis delta

The new data, if confirmed, marginally increases the probability of the bull scenario by strengthening the nHCM indication and possibly enhancing differentiation. However, it does not materially alter the base or bear cases, as commercial execution and balance-sheet risks remain the dominant drivers. The thesis's reduce/avoid stance remains appropriate until launch data and ACACIA results are fully vetted.